Anika Therapeutics, Inc.
A maker of joint-preservation and tissue-repair products built on hyaluronic acid — the same slippery substance that naturally cushions human joints. Its injectable treatments Orthovisc, Monovisc, and CINGAL ease osteoarthritis knee pain, while its surgical implants help regenerate torn tendons. Formed in 1992 as a spin-off of MedChem Products, this Bedford, Massachusetts company's products were long sold in the US under the Johnson & Johnson brand rather than its own name.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Vanguard Capital Management | 13G/APassive | 4.95% | 659.2K | Jul 31, 2026 |
| BlackRock Portfolio Management LLC | 13G/APassive | 4.1% | 544.7K | Jul 17, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| Caligan Partners LP | 13D/AActivist | 9.95% | 1.44M | Jan 27, 2026 |
| David Johnson | 13D/AActivist | 9.95% | 1.44M | Jan 27, 2026 |
| Trigran Investments, Inc. | 13G/APassive | 1.2% | 168.4K | Jan 8, 2026 |
| Douglas T. Granat | 13G/APassive | 1.2% | 168.4K | Jan 8, 2026 |
| Lawrence A. Oberman | 13G/APassive | 1.2% | 168.4K | Jan 8, 2026 |
| Steven G. Simon | 13G/APassive | 1.2% | 168.4K | Jan 8, 2026 |
| Bradley F. Simon | 13G/APassive | 1.2% | 168.4K | Jan 8, 2026 |